EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Romidepsin Suppresses ESCC Cell Proliferation and Progression via HDAC2-H3K14ac-p53 Pathway

Xinfeng Zhou iD, Yong Zang iD, Chen Chen iD, Jianji Zhang iD, Jianan Wang iD, Xinyun Zhang iD, Xue Bai iD, Yanpu Han iD, Kai Zhang iD

Genomics, Proteomics & Bioinformatics · 14.11.2026

DOI: 10.1093/gpbjnl/qzag112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genomics, Proteomics & Bioinformatics, online erschienen am 14.11.2026. Verfasst von Xinfeng Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylase 2 (HDAC2) may contribute to epigenetic dysregulation in esophageal squamous cell carcinoma (ESCC) by silencing tumor suppressor genes, yet isoform-specific therapeutic targeting remains underexplored. Here, we show that romidepsin, an FDA-approved class I HDAC inhibitor, preferentially inhibits HDAC2-associated deacetylation in ESCC cells. We identified romidepsin as a potent inhibitor of ESCC cell viability, through phenotypic screening of 773 epigenetic compounds across differentiation-stage-defined ESCC models. Multi-omics analyses (SILAC proteomics, CUT&Tag chromatin mapping, and RNA-seq) further revealed histone H3K14ac enrichment at promoters of p53 pathway targets, including CDKN1A/p21, which exhibited transcriptional reactivation. Similar to HDAC2 knockout, romidepsin suppressed ESCC proliferation, migration, and clonogenicity. Mechanistically, HDAC2 inhibition reverses epigenetic silencing of p21 and restores tumor-suppressive chromatin states. Together, these results identify the HDAC2–H3K14ac axis as a therapeutic vulnerability in ESCC and provide preclinical support for romidepsin-based epigenetic intervention.

Schlagwörter

Stichwörter der Autor:innen

Cell proliferationEsophageal squamous cell carcinomaHDAC2Histone H3K14acProteomics

Autor:innen und Institutionen

  • Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory of Cellular and Molec…
  • Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
  • State Key Laboratory of Experimental Hematology, Tianjin Medical University, Tianjin 300070, China.

ORCID-Profile: Xinfeng Zhou, Yong Zang, Chen Chen, Jianji Zhang, Jianan Wang, Xinyun Zhang, Xue Bai, Yanpu Han, Kai Zhang

Zitieren

APA

Zhou, X., Zang, Y., Chen, C., Zhang, J., Wang, J., Zhang, X., Bai, X., Han, Y., & Zhang, K. (2026). Romidepsin Suppresses ESCC Cell Proliferation and Progression via HDAC2-H3K14ac-p53 Pathway. Genomics, Proteomics & Bioinformatics. https://doi.org/10.1093/gpbjnl/qzag112

Vancouver

Zhou X, Zang Y, Chen C, Zhang J, Wang J, Zhang X, et al. Romidepsin Suppresses ESCC Cell Proliferation and Progression via HDAC2-H3K14ac-p53 Pathway. Genomics, Proteomics & Bioinformatics. 2026. doi:10.1093/gpbjnl/qzag112

BibTeX
@article{Zhou2026,
  author = {Zhou, Xinfeng and Zang, Yong and Chen, Chen and Zhang, Jianji and Wang, Jianan and Zhang, Xinyun and Bai, Xue and Han, Yanpu and Zhang, Kai},
  title = {Romidepsin Suppresses ESCC Cell Proliferation and Progression via HDAC2-H3K14ac-p53 Pathway},
  journal = {Genomics, Proteomics & Bioinformatics},
  year = {2026},
  doi = {10.1093/gpbjnl/qzag112}
}
Kostenlos starten →